Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 1099-1102

  Mustea, Alexander ^a   Sehouli, Jalid ^a   Könsgen, Dominique ^a   Stengel, Dirk ^b   Sofroni, Dumitru ^b   Lichtenegger, Werner ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Dept of Traumatolgy/Emergency Hosp ^*

Author keywords

Cervical cancer; Interleukin 1 receptor antagonist; Polymorphism

Indexed keywords

GENOMIC DNA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; CANCER GRADING; CANCER RECURRENCE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC CODE; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MARKER GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KERATINS; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SIALOGLYCOPROTEINS; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 0038544607     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Landis SH, Murray T and Bolden S: Cancer statistics. CA Cancer J Clin: 8: 49-54, 1999.
2. Gabunea M and Sofroni D: Cancer Register of Moldawien Oncological Institute. Annual Report 1, 16-21, 2001
3. Meanwell CA: The epidemiology and etiology of cervical cancer. In: Blackledge GRP, Jordan JA et al. Textbook of Gynecological Oncology. (Philadelphia: WB Saunders), 250-256, 1991
4. th; 1526-50, 2001.
5. Walker J, Bloss JD, Liao SY, Berman M, Bergen S and Wilczynski SP: Human papillomavirus genotype as a prognostic indicator in carcinoma of the uterine cervix. Obstet Gynecol 74(5): 781-785, 1989.
6. Buehler JW, Hanson DL and Chu SY: The reporting of HIV/AIDS death in women. Am J Public Health 82: 1360-1378, 1992.
7. Castello G, Espositio E, Stellato G et al: Immunological abnormalities in patients with cervical carcinoma. Gynecol Oncol 26: 605-611, 1986.
8. Schwartz LB, Cargangiu ML, Bradham L et al: Rapidly progressive squamous cell carcinoma coexisting with human immunodeficiency virus infection: clinical opinion. Gynecol Oncol 41: 250-255, 1991.
9. Serur E, Fruchter RG, Maiman M et al: Age, substance abuse, and survival of patients with cervical carcinoma. Cancer 75: 2340-450, 1995.
10. Farnceschi S, Dal Maso L, Arniani S et al: Risk of cancer other then Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 78: 959-966, 1998.
11. Punnonen J, Heinonen PK, Kuoppala T et al: Production of interleukin 1 beta and tumor necrosis factor-alpha in patients with benign or malignant ovarian tumours. J Cancer Res Clin Oncol 117: 587-92, 1991.
12. Kim KY, Jeong SY, Won J, Ryu PD and Nam MJ: Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma. J Biol Chem 19: 276-79, 2001.
13. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H and Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17(7): 4015-4023, 1997.
14. Tepper RI, Pattengale PK and Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57(3): 503-512, 1989.
15. Irvine KR, Rao JB, Rosenberg SA and Restifo NP: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156(1): 238-245, 1996.
16. Dinarello CA:. Interleukin-1 and interleukin-1 antagonism. Blood 77: 1627-1652, 1991.
17. Dinarello CA and Thompson RC: Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol To-day 12: 404-410, 1991.
18. Castrilli G and Tatone A: IL-1alfa promote growth of neoplastic human cervical cells Br. J Cancer 75 (6): 855-859, 1997.
19. Arend WP: Interleukin 1 receptor antagonist: Discovery, structure and properties. Prog Growth Factor Res 2: 193-205, 1990.
20. Van Le L, Haskill S, Jaffe GJ and Fowler WC: Expression of interleukin 1 and interleukin 1 receptor antagonist in endometrial cancer. Gynecol Oncol 42: 161-164, 1991.
21. Smith DR, Kunkel SL, Standiford TJ et al: The production of interleukin 1 receptor antagonist by human bronchogenic carcinoma. Am J Pathol 143: 794-803, 1993.
22. Oelmann, E, Kraemer A, Serve H et al: Autocrine interleukin 1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin 1. Int J Cancer 71: 1066-1076, 1997.
23. Iizuka N, Hazama S and Hirose K: Interleukin 1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Lett 142: 179-184, 1999.
24. Fujiwaki R, Hata T, Miyazaki K, Kawamura T and Inada K: Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers. Br J Obstet Gynaecol 104(12): 1407-1408, 1997.
25. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147 1996.
26. Tseng LH and Chen PJ: Single nucleotide polymorphisms in Intron 2 of the human IL-1 RA. Tissue Antigens 57: 318-324, 2001.
27. Tarlow JK, Blakemore AIF, Lennard A, Solari R, Hughes HN, Steinkasserer A and Duff GW: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91: 403-404, 1993.
28. Jeremias J, Ledger WJ and Witkin S: Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis Am J Obstet Gynecol 182 (2): 283-285, 2000.
29. Bidwell J, Keen L, Gallagher G et al.: Cytokine gene polymorphism in human disease: on-line databases. Genes Immunity 1: 3-19, 1999.
30. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr and Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 23: 404(6776): 398-402, 2000.
31. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F and Sobrinho-Simoes M: Interleukin 1b and Interleukin 1RN polymorphisms are associated with Increased risk of gastric carcinoma. Gastroenterology 121: 823-829, 2001.
32. Strauss JF: Unravelling the genetics of complex disorders of reproduction. In: Countinuto EM.. Reproductive Medicine: A Millennium Review.(Spinola P. eds), New-York: The Parthenom Publishing Group; 1999. p. 284-287.
33. Santtila S, Savinainen K and Hurme M: Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47(3): 195-8, 1998.
34. Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, Chipato T, Ngwalle S, Munjoma M and Shah KV: HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 15, 85(2): 206-210, 2000.
35. Frazer IH: Immunology of papillomavirus infection. Curr Opin Immunol 8(4): 484-91. Review, 1996.
36. Unfried G, Tempfer C, Schneeberger C, Widmar B, Nagele F and Huber JC: Interleukin 1 receptor antagonist polymorphism in women with idiopathic recurrent miscarriage. Fertil Steril 75(4): 683-687, 2001.